Taken together, these findings suggest that signaling through SLAMF1 may be dysregulated in CLL cells compared to normal peripheral blood B cells, and that the degree of dysregulation may be reflected in more aggressive clinical behavior. The gene discussed is SLAMF1; the disease is B-cell chronic lymphocytic leukemia.